Lexeo Therapeutics (NASDAQ:LXEO) CFO Sells 4,641 Shares

Posted by Stanley Muller on Jul 1st, 2026

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) CFO Louis Edward Tamayo sold 4,641 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.49, for a total value of $20,838.09. Following the completion of the sale, the chief financial officer owned 97,024 shares of the company’s stock, valued at approximately $435,637.76. This trade represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Trading Down 4.5%

Shares of LXEO stock traded down $0.21 during trading hours on Wednesday, reaching $4.45. 852,557 shares of the company’s stock were exchanged, compared to its average volume of 948,339. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The stock has a market cap of $349.41 million, a PE ratio of -3.07 and a beta of 1.38. The stock’s fifty day moving average price is $5.16 and its two-hundred day moving average price is $6.67.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, equities analysts expect that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. Bank of America Corp DE boosted its holdings in Lexeo Therapeutics by 206.7% in the 1st quarter. Bank of America Corp DE now owns 491,532 shares of the company’s stock worth $2,821,000 after buying an additional 331,244 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Lexeo Therapeutics by 5.3% in the first quarter. ADAR1 Capital Management LLC now owns 1,467,350 shares of the company’s stock valued at $8,423,000 after acquiring an additional 74,189 shares in the last quarter. Orbimed Advisors LLC boosted its stake in shares of Lexeo Therapeutics by 69.5% in the first quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock worth $20,678,000 after acquiring an additional 1,477,450 shares during the last quarter. Affinity Asset Advisors LLC increased its position in shares of Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. Finally, Spruce Street Capital LP boosted its stake in Lexeo Therapeutics by 430.6% during the 1st quarter. Spruce Street Capital LP now owns 928,593 shares of the company’s stock worth $5,330,000 after purchasing an additional 753,593 shares during the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LXEO shares. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Weiss Ratings lowered shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. Finally, Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $18.75.

Check Out Our Latest Analysis on Lexeo Therapeutics

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.